Dignify Therapeutics, a biotechnology company dedicated to restoring voluntary bowel and bladder function in patients with ...

Fintel reports that on February 13, 2025, UBS initiated coverage of Celldex Therapeutics (NasdaqCM:CLDX) with a Buy ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.86, a high estimate of $14.00, ...

Q4 2024 Earnings Call Transcript February 7, 2025 Iterum Therapeutics plc beats earnings expectations. Reported EPS is $-0.12 ...

Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment ContinuesPromising Data, including a 59% Stable ...

Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders –– Capital raising was strongly supported by domestic and ...

Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, ...

Travere Therapeutics aims to seek traditional approval based on data from the Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI, with submission expected by the end of the first quarter of 2025. The ...

Axsome's CEO, Herriot Tabuteau, MD, expressed pride in the company's commitment to improving patient outcomes and emphasized ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...